PRTK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 Sep 2023 @ 22:00):

Stats
Tagesvolumen	4.48M
Durchschnittsvolumen	599 679
Marktkapitalisierung	127.83M
EPS	$0 ( 2024-03-14 )
Nächstes Ertragsdatum	( $0 ) 2024-05-07
Last Dividend	$0.667 ( 2014-10-31 )
Next Dividend	$0 ( N/A )
P/E	-2.01
ATR14	$0.0250 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-21	Baylor-henry Minnie	Sell	32 800	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	26 400	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	12 800	Stock option (right to buy)
2023-09-21	Hoffmann Rolf K	Sell	64 000	Common Stock
2023-09-21	Hoffmann Rolf K	Sell	20 000	Common Stock

INSIDER POWER
-64.23
Last 96 transactions
Buy: 1 606 755 \| Sell: 5 363 965

Volumen Korrelation

Lang: 0.14 (neutral)

Kurz: 0.00 (neutral)

Signal:(59.187) Neutral

Paratek Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
PAIC	0.948
SVOK	0.947
BIOL	0.912
RMRM	0.909
YMAB	0.899
SVAC	0.89
AVCT	0.883
TSP	0.879
UK	0.876
GAINL	0.876

10 Am meisten negativ korreliert
BOCH	-0.954
NETE	-0.938
MMAC	-0.912
RAVN	-0.903
SHSP	-0.9
LMRK	-0.894
QADA	-0.878
VLYPO	-0.862
AMRB	-0.862
PODD	-0.858

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Paratek Pharmaceuticals Korrelation - Währung/Rohstoff

0.48
( neutral )

0.40
( neutral )

0.00
( neutral )

0.53
( weak )

0.32
( neutral )

-0.23
( neutral )

Paratek Pharmaceuticals Finanzdaten

Annual	2022
Umsatz:	$150.79M
Bruttogewinn:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2022
Umsatz:	$150.79M
Bruttogewinn:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2021
Umsatz:	$130.16M
Bruttogewinn:	$108.63M (83.46 %)
EPS:	$-1.201

FY	2020
Umsatz:	$46.92M
Bruttogewinn:	$38.27M (81.56 %)
EPS:	$-2.19

Financial Reports:

No articles found.

Paratek Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Paratek Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.312 - low (50.00%) | Divividend Growth Potential Score: 0.170 - No dividend growth expected in the near future

Information

First Dividend	$15.96	2014-05-21
Last Dividend	$0.667	2014-10-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	$40.59	--
Avg. Dividend % Per Year	0.00%	--
Score	1.91	--
Div. Sustainability Score	0.312
Div.Growth Potential Score	0.170
Div. Directional Score	0.241	--

Next Divdend (Est)
(2024-10-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.91

Pay Frequency

Bi-Monthly

Yearly Payout

Year	Amount	Yield
2014	$40.59	172.60%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.299	1.500	-5.98	-8.98	[0 - 0.5]
returnOnAssetsTTM	-0.287	1.200	-9.57	-10.00	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.63	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.519	0.800	-2.40	-1.923	[1 - 3]
quickRatioTTM	0.420	0.800	-2.23	-1.786	[0.8 - 2.5]
cashRatioTTM	0.211	1.500	9.94	10.00	[0.2 - 2]
debtRatioTTM	1.782	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-1.959	1.000	-1.837	-1.837	[3 - 30]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0949	-0.190	[0 - 20]
debtEquityRatioTTM	-1.290	-1.500	-5.16	7.74	[0 - 2.5]
grossProfitMarginTTM	0.850	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.201	1.000	-6.01	-6.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0416	1.000	-1.342	-1.342	[0.2 - 2]
assetTurnoverTTM	0.960	0.800	6.94	5.55	[0.5 - 2]
Total Score				0.312

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.05	1.000	-0.409	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.12	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0632	-0.190	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.179	1.500	-2.14	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0772	1.000	-4.43	0	[0.1 - 0.5]
Total Score				0.170

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.